Drug Trial Radar · NCT06151808
Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects
Last checked: Nov 19, 2026Latest source record: May 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Sep 1, 2022
Primary completion
Nov 28, 2023
Study completion Jan 10, 2024
Sponsor
- Lead sponsor
- Sinotau Pharmaceutical GroupIndustry
- Sponsor type
- Industry
- First posted
- Nov 30, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive impairment(MCI)due to AD and mild to moderate AD based on clinical diagnosis, and to establish XTR006 PET imaging parameters and qualitative reading and quantitative analysis methods.
Conditions
- Alzheimer Disease
Interventions
XTR006Drug
All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan
Primary outcomes
What the sponsor says the trial is designed to measure.
- To investigate the sensitivity and specificity of XTR006 PET imaging by readingTime frame: day 1
- To investigate the sensitivity and specificity of XTR006 PET imaging by SUVRTime frame: day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.